Featured Research

from universities, journals, and other organizations

Workers With Carpal Tunnel Find Relief With Night-time Splinting

Date:
January 10, 2005
Source:
University Of Michigan Health System
Summary:
After a long day on the job, tired minds and sore feet look forward to a long night of rejuvenating rest. A new study finds that nocturnal rest can do a world of good for your hands and wrists too, especially if you are one of the millions of American workers who are just beginning to feel the common pain and discomfort linked to carpal tunnel syndrome.

Carpal tunnel splint.
Credit: Photo courtesy of University Of Michigan Health System

ANN ARBOR, Mich. – After a long day on the job, tired minds and sore feet look forward to a long night of rejuvenating rest. A new study finds that nocturnal rest can do a world of good for your hands and wrists too, especially if you are one of the millions of American workers who are just beginning to feel the common pain and discomfort linked to carpal tunnel syndrome.

The findings, made by a team of researchers with the University of Michigan Health System and the VA Ann Arbor Healthcare System, show that night-time splinting can effectively improve hand and wrist discomfort for active workers with early symptoms of carpal tunnel syndrome.

The results from the study are published in the January issue of the Archives of Physical Medicine and Rehabilitation.

While carpal tunnel syndrome is a common work-related disorder and a major cause of impairment and disability in the workplace, the use of initial medical treatment protocols for the disorder – wrist splints, modification of hand activity, non-steroidal anti-inflammatory medication, diuretics and steroid injections – have widely varied across the United States and Western Europe, says lead author Robert A. Werner, M.D., MS, professor in the Department of Physical Medicine and Rehabilitation at the U-M Health System.

"Workers with carpal tunnel syndrome have more lost work time than any other work-related injury. Additionally, CTS is frequently misdiagnosed and there's very little scientific research to show which initial treatments are actually the most effective for those with symptoms of carpal tunnel syndrome," says Werner, the chief of Physical Medicine and Rehabilitation at the VA Ann Arbor Healthcare System and an associate research scientist with the U-M Center for Ergonomics.

The first line of conservative treatment for carpal tunnel syndrome, both from doctors and self-prescribed, is typically nocturnal splinting. Splinting, Werner says, reduces stress on the peripheral nerve in the wrist, allowing it to heal and avoids awkward wrist positions as a person sleeps. It is not recommended for active day-time use when workers are active because it may cause additional strain on the wrist.

To determine the effectiveness of nocturnal splinting, Werner and his colleagues studied 112 active workers at a Midwestern automotive assembly plant with symptoms consistent of carpal tunnel but who had not sought medical treatment.

Subjects were selected if they experienced numbness, tingling, burning or pain in the median nerve of the hand for more than a week or for more than three times in the past six months. Werner notes that automotive assembly workers are five to ten times more likely to develop carpal tunnel than people than the general population and people who type for a living. Workers in the group too, miss, on average, a month of work, especially those who seek surgical intervention for advanced symptoms of carpal tunnel.

As part of the randomized controlled study, 63 study participants were fitted with a custom wrist-hand splint that maintained the wrist in a neutral posture overnight and were instructed to wear the splint at night for a period of six weeks. This group, along with the remaining 49 participants, also viewed a 20-minute video on carpal tunnel syndrome and how to reduce ergonomic stressors at work and home.

After the six week trial, about half of the splinted group reported significant improvement in their symptoms, with one participant reporting complete relief of symptoms. Compared to the group assigned to just watch the video, the splinted group had significantly decreased hand, wrist, elbow and forearm discomfort after three months.

After 12 months, the improvement seen in each group was greatly dependent on the individual's level of hand/wrist nerve damage. Of those in the non-splinted group, participants with healthy nerves noted reduced hand/wrist discomfort, while those with injured nerves felt no improvement over time.

Those who used the splint – both with healthy and injured nerves – saw significant improvement in hand/wrist discomfort, and participants who initially reported higher levels of discomfort at the start of the study saw the greatest improvements with splint use. Additionally, 10 percent of the participants in this group continued to wear the splint at night beyond the initial six-week trial.

Prior to the study, nearly half of the participants used non-steroidal anti-inflammatory drugs and ice/heat treatments to treat their hand and wrist discomfort, while less than 25 percent had previously sought physical therapy for their carpal tunnel symptoms.

Despite relief from NSAIDs and other home remedies, Werner says using a custom fit or store-bought splint for night-time use is the best first line of defense when symptoms of carpal tunnel begin. Splinting, he notes, has minimal effect on those with advanced carpal tunnel.

"Early intervention with splinting is key to effective management of carpal tunnel syndrome," says Werner. "It's very cost-effective and the odds are very good that you will feel the benefits." Werner hopes to build on the findings from this study by conducting a larger study to determine the cost-effectiveness of splinting and its long-term benefits for patients.

In addition to Werner, the study was co-authored by Alfred Franzblau, M.D., associate professor in the UMHS Department of Emergency Medicine, associate research scientist at the U-M Center for Ergonomics and professor in the Department of Environmental Health Sciences at the U-M School of Public Health; and Nancy Gell, MPH, PT, a research associate in the UMHS Department of Physical Medicine and Rehabilitation and the U-M School of Public Health's Department of Environmental Health Sciences.

###

The study was funded by the UAW-GM National Joint Committee on Health and Safety. Reference: Archives of Physical Medicine and Rehabilitation, January 2005, Vol. 86, No. 1.


Story Source:

The above story is based on materials provided by University Of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan Health System. "Workers With Carpal Tunnel Find Relief With Night-time Splinting." ScienceDaily. ScienceDaily, 10 January 2005. <www.sciencedaily.com/releases/2005/01/050106112808.htm>.
University Of Michigan Health System. (2005, January 10). Workers With Carpal Tunnel Find Relief With Night-time Splinting. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/01/050106112808.htm
University Of Michigan Health System. "Workers With Carpal Tunnel Find Relief With Night-time Splinting." ScienceDaily. www.sciencedaily.com/releases/2005/01/050106112808.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins